you are here: Home News Sun Pharmaceuticals

Sun Pharmaceuticals

Sun Pharma: Checkpoint acquisition strengthens speciality portfolio
Buy Sun Pharmaceuticals; target of Rs 2264: Sharekhan
Buy Sun Pharmaceuticals; target of Rs 1800: Sharekhan
Buy Sun Pharmaceuticals; target of Rs 1827: KR Choksey
Sun Pharma, Lupin, Alkem recall products from US market
Sun Pharma hits 52-week high on acquiring Israeli company
Top Nifty gainers and losers at mid-day: Hindalco up, Power Grid down
Improved sentiment, hopes of better sales fuel gains in pharma stocks; Divi's Lab spurts 8%
Taken prompt steps to contain impact of IT security incident, ransomware group claims responsibility: Sun Pharma
Sun Pharma to get growth boost with addition of Deuroxolitinib to its speciality portfolio: Analysts
Quant Pick - Sun Pharmaceuticals: ICICI Direct
Buy Sun Pharmaceuticals; target of Rs 660: Dolat Capital
Buy Sun Pharmaceuticals; target of Rs 571: Dolat Capital
Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital
Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital
Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct
Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct
Buy Sun Pharmaceuticals; target of Rs 690: ICICI Direct
Sun Pharma recalls over 5.2k units of testosterone cypionate injections from US
Sun Pharmaceuticals Q1 PAT seen up 68.7% YoY to Rs. 886.9 cr: Kotak
Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss
Hold Sun Pharmaceuticals; target of Rs 510: ICICI Direct
Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss
Sun Pharmaceuticals Q2 PAT may dip 62.3% YoY to Rs. 848.7 cr: Kotak
Analysts consensus is bearish on pharma stocks – should one buy?

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Sun Pharmaceuticals

Sun Pharma: Checkpoint acquisition strengthens speciality portfolio

Buy Sun Pharmaceuticals; target of Rs 2264: Sharekhan

Buy Sun Pharmaceuticals; target of Rs 1800: Sharekhan

Buy Sun Pharmaceuticals; target of Rs 1827: KR Choksey

Sun Pharma, Lupin, Alkem recall products from US market

Sun Pharma hits 52-week high on acquiring Israeli company

Top Nifty gainers and losers at mid-day: Hindalco up, Power Grid down

Improved sentiment, hopes of better sales fuel gains in pharma stocks; Divi's Lab spurts 8%

Taken prompt steps to contain impact of IT security incident, ransomware group claims responsibility: Sun Pharma

Sun Pharma to get growth boost with addition of Deuroxolitinib to its speciality portfolio: Analysts

Quant Pick - Sun Pharmaceuticals: ICICI Direct

Buy Sun Pharmaceuticals; target of Rs 660: Dolat Capital

Buy Sun Pharmaceuticals; target of Rs 571: Dolat Capital

Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital

Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital

Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct

Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct

Buy Sun Pharmaceuticals; target of Rs 690: ICICI Direct

Sun Pharma recalls over 5.2k units of testosterone cypionate injections from US

Sun Pharmaceuticals Q1 PAT seen up 68.7% YoY to Rs. 886.9 cr: Kotak

Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss

Hold Sun Pharmaceuticals; target of Rs 510: ICICI Direct

Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss

Sun Pharmaceuticals Q2 PAT may dip 62.3% YoY to Rs. 848.7 cr: Kotak

Analysts consensus is bearish on pharma stocks – should one buy?